Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. PHR
PHR logo

PHR Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
10.530
Open
10.360
VWAP
10.34
Vol
1.89M
Mkt Cap
640.37M
Low
10.135
Amount
19.50M
EV/EBITDA(TTM)
14.07
Total Shares
61.81M
EV
674.81M
EV/OCF(TTM)
7.68
P/S(TTM)
1.33
Phreesia, Inc. is a provider of comprehensive software solutions that improve the operational and financial performance of healthcare organizations. The Company's solutions include software-as-a-service (SaaS)-based integrated tools that manage patient access, registration, and payments. In addition, its solutions include clinical assessments to screen patients for a variety of physical, behavioral and mental health conditions, helping providers to understand their patients and connect them to needed services, resulting in improved health outcomes. Its Technology solutions segment provides life sciences companies, health plans and other payer organizations (payers), patient advocacy, public interest and other not-for-profit organizations with a channel for direct communication with patients. The Company's solutions also include additional products and services, such as the MediFind provider directory, which helps patients find care based on providers' specific clinical expertise.
Show More

Events Timeline

(ET)
2026-05-27
19:50:00
WTI Crude Oil Falls Below $90, Energy Sector Worst Performer
select
2026-05-27
16:30:00
Phreesia Up 12% to $10.21 After Q1 Results, Affirms Guidance
select
2026-05-27
16:30:00
Phreesia Maintains Fiscal 2027 Revenue Outlook at $510M to $520M
select
2026-05-27
16:10:00
Phreesia Q1 Revenue $130.9M, Beats Expectations
select
2026-05-20 (ET)
2026-05-20
16:20:00
Major Averages Close Broadly Higher as Oil Prices Slip Below $100
select
2026-05-20
11:50:00
Major Averages Rise as Semiconductor Stocks Rebound
select

News

Globenewswire
7.0
20:47 PMGlobenewswire
Phreesia Faces Class Action Lawsuit Amid Revenue Downgrade
  • Class Action Filed: Pomerantz LLP has announced a class action lawsuit against Phreesia, alleging securities fraud and other unlawful business practices, with investors needing to apply as Lead Plaintiff by July 13, 2026.
  • Revenue Guidance Downgrade: On March 30, 2026, Phreesia significantly reduced its revenue growth projections for fiscal year 2027, citing macroeconomic factors such as worsening visibility and weaker pharmaceutical marketing commitments affecting its Network Solutions segment.
  • Stock Price Plunge: Following the revenue downgrade, Phreesia's stock price fell by $3.03, or 26.56%, closing at $8.38 per share on March 31, 2026, indicating market pessimism regarding the company's future outlook.
  • Legal Firm Background: Pomerantz LLP is a prominent law firm specializing in class action litigation, with a long history of recovering multimillion-dollar damages for victims of securities fraud, showcasing its expertise in handling complex securities cases.
Globenewswire
7.0
17:46 PMGlobenewswire
Phreesia Investors Class Action Reminder
  • Lawsuit Background: On March 30, 2026, Phreesia announced significantly lowered revenue growth projections for fiscal 2027, resulting in a 26.6% drop in stock price to $8.38 per share the following day, causing substantial losses for investors.
  • False Information Allegations: The complaint alleges that throughout the class period, the company misled investors by projecting confidence in its long-term growth outlook while downplaying risks associated with slowing growth in its Network Solutions segment.
  • Class Action Deadline: Investors must file a lead plaintiff motion by July 13, 2026, to seek compensation for losses incurred during the class period, emphasizing the urgency for affected shareholders to act.
  • Legal Consultation Information: Glancy Prongay Wolke & Rotter LLP offers legal consultation, encouraging investors to reach out via email or phone for further information to ensure their rights are protected.
Globenewswire
7.0
06-01Globenewswire
Reminder of Phreesia Stock Class Action Lawsuit
  • Class Action Notification: Rosen Law Firm reminds investors who purchased Phreesia (NYSE: PHR) common stock between May 8, 2025, and March 30, 2026, to apply as lead plaintiffs by July 13, 2026, or risk not being represented in the class action lawsuit.
  • Fee Arrangement: Participants can receive compensation without any upfront costs through a contingency fee arrangement, which alleviates the financial burden on investors and encourages more affected shareholders to join the lawsuit.
  • Lawsuit Background: The lawsuit alleges that Phreesia made false and misleading statements during the class period, concealing adverse facts such as weakened pharmaceutical marketing commitments in its Network Solutions segment, leading to investor losses when the truth emerged.
  • Law Firm's Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, ranked first in 2017 for the number of settlements, demonstrating its expertise and success in this legal domain.
Globenewswire
7.0
06-01Globenewswire
Phreesia Faces Class Action Lawsuit; Investors Encouraged to Contact Attorneys
  • Class Action Initiated: Bragar Eagel & Squire has filed a class action lawsuit against Phreesia in the U.S. District Court for Delaware on behalf of investors who purchased shares between May 8, 2025, and March 30, 2026, highlighting significant concerns regarding the company's financial transparency.
  • Allegation Details: The complaint alleges that Phreesia and its executives violated federal securities laws by failing to disclose the true state of slowing demand and reduced visibility in key revenue streams, particularly the weakened pharmaceutical marketing commitments in its Network Solutions segment, potentially leading to investor losses.
  • Revenue Guidance Downgrade: In its Q4 2026 earnings release, Phreesia lowered its fiscal 2027 revenue guidance to $510 million to $520 million, down from $545 million to $559 million, reflecting the market challenges the company is facing.
  • Stock Price Impact: Following the revenue guidance downgrade, Phreesia's stock price fell by 21% to 28%, indicating market concerns about the company's future performance, prompting investors to stay informed about their legal rights.
Globenewswire
7.0
06-01Globenewswire
Reminder of Shareholder Class Action Lawsuits
  • Lawsuit Overview: Holzer & Holzer, LLC reminds investors of a class action lawsuit against Graphic Packaging Holding Company, alleging that the company failed to disclose critical inventory management information between February 2025 and February 2026, resulting in investor losses.
  • Key Deadlines: Investors must apply to be appointed lead plaintiff by July 6, 2026, to protect their legal rights, with similar lawsuits also filed against Immutep Limited and Phreesia, Inc.
  • Legal Consultation Access: Affected investors are encouraged to contact Holzer & Holzer through their website or toll-free number to learn more about their legal rights and ensure timely action.
  • Law Firm Credentials: Holzer & Holzer, LLC is a top-rated securities litigation law firm recognized for its vigorous representation of shareholders, having recovered hundreds of millions of dollars for defrauded investors since its inception in 2000, showcasing its expertise in protecting investor interests.
Globenewswire
7.0
06-01Globenewswire
Phreesia Faces Securities Class Action Lawsuit
  • Significant Stock Decline: Phreesia's shares fell approximately 27% on March 31, 2026, losing $3.03 per share to close at $8.38, primarily due to the company's downward revision of its fiscal 2027 revenue outlook from $545-$559 million to $510-$520 million, which directly impacts investor confidence and market performance.
  • Class Action Initiation: The securities class action against Phreesia and certain executives alleges that they disseminated materially misleading statements regarding fiscal 2027 revenue growth prospects while concealing deteriorating pharmaceutical marketing commitments in the Network Solutions segment, potentially exposing investors to legal liabilities and financial losses.
  • Investor Obligations: Institutional investors holding PHR securities must evaluate potential recovery options for losses, as failing to do so may raise questions about their fiduciary duties, especially in the context of alleged securities fraud, necessitating active participation in the litigation to protect their interests.
  • Lead Plaintiff Opportunities: Institutional investors can apply to become lead plaintiffs, allowing them direct oversight of litigation strategy and settlement terms without incurring out-of-pocket costs, as attorney fees will be paid from any recovery, ensuring their proactive role and maximization of interests in the legal process.
Wall Street analysts forecast PHR stock price to rise
12 Analyst Rating
Wall Street analysts forecast PHR stock price to rise
12 Buy
0 Hold
0 Sell
Strong Buy
Current: 0.000
sliders
Low
24.00
Averages
29.09
High
35.00
Current: 0.000
sliders
Low
24.00
Averages
29.09
High
35.00
Piper Sandler
Overweight
to
Neutral
downgrade
$23 -> $12
AI Analysis
2026-05-28
New
Reason
Piper Sandler
Price Target
$23 -> $12
AI Analysis
2026-05-28
New
downgrade
Overweight
to
Neutral
Reason
Piper Sandler downgraded Phreesia to Neutral from Overweight with a price target of $12, down from $23.
Piper Sandler
Jessica Tassan
Overweight
to
Neutral
downgrade
$23 -> $12
2026-05-28
New
Reason
Piper Sandler
Jessica Tassan
Price Target
$23 -> $12
2026-05-28
New
downgrade
Overweight
to
Neutral
Reason
Piper Sandler analyst Jessica Tassan downgraded Phreesia to Neutral from Overweight with a price target of $12, down from $23. Phreesia is cutting costs to find profitability, but without a clear path back to durable organic revenue growth, notes the analyst, who is \"wary of this strategy\" in healthcare IT.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for PHR
Unlock Now

Valuation Metrics

The current forward P/E ratio for Phreesia Inc (PHR.N) is 13.14, compared to its 5-year average forward P/E of -1.22. For a more detailed relative valuation and DCF analysis to assess Phreesia Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.22
Current PE
13.14
Overvalued PE
188.62
Undervalued PE
-191.05

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-26.62
Current EV/EBITDA
10.08
Overvalued EV/EBITDA
93.28
Undervalued EV/EBITDA
-146.53

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
4.72
Current PS
1.13
Overvalued PS
8.55
Undervalued PS
0.90

Financials

AI Analysis
Annual
Quarterly

Whales Holding PHR

G
Granahan Investment Management, LLC
Holding
PHR
+11.96%
3M Return
R
Rock Springs Capital Management LP
Holding
PHR
+4.02%
3M Return
D
Deerfield Management Company, L.P.
Holding
PHR
+0.81%
3M Return
G
Greenhouse Funds LLLP
Holding
PHR
-5.93%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Phreesia Inc (PHR) stock price today?

The current price of PHR is 10.36 USD — it has decreased -2.81

What is Phreesia Inc (PHR)'s business?

Phreesia, Inc. is a provider of comprehensive software solutions that improve the operational and financial performance of healthcare organizations. The Company's solutions include software-as-a-service (SaaS)-based integrated tools that manage patient access, registration, and payments. In addition, its solutions include clinical assessments to screen patients for a variety of physical, behavioral and mental health conditions, helping providers to understand their patients and connect them to needed services, resulting in improved health outcomes. Its Technology solutions segment provides life sciences companies, health plans and other payer organizations (payers), patient advocacy, public interest and other not-for-profit organizations with a channel for direct communication with patients. The Company's solutions also include additional products and services, such as the MediFind provider directory, which helps patients find care based on providers' specific clinical expertise.

What is the price predicton of PHR Stock?

Wall Street analysts forecast PHR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PHR is29.09 USD with a low forecast of 24.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Phreesia Inc (PHR)'s revenue for the last quarter?

Phreesia Inc revenue for the last quarter amounts to 130.94M USD, increased 12.94

What is Phreesia Inc (PHR)'s earnings per share (EPS) for the last quarter?

Phreesia Inc. EPS for the last quarter amounts to 0.05 USD, decreased -171.43

How many employees does Phreesia Inc (PHR). have?

Phreesia Inc (PHR) has 1789 emplpoyees as of June 02 2026.

What is Phreesia Inc (PHR) market cap?

Today PHR has the market capitalization of 640.37M USD.